Randall Michael Giuffre - 03 Jan 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Amy Culbert, attorney-in-fact
Issuer symbol
DMAC
Transactions as of
03 Jan 2022
Net transactions value
+$53,793
Form type
4
Filing time
03 Jan 2022, 15:09:49 UTC
Previous filing
16 Jul 2021
Next filing
02 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAC Voting Common Shares, no par value per share Award $53,793 +15,026 +16% $3.58 110,225 03 Jan 2022 Direct F1, F2, F3
holding DMAC Voting Common Shares, no par value per share 25,573 03 Jan 2022 See footnote F4
holding DMAC Voting Common Shares, no par value per share 21,070 03 Jan 2022 By Spouse
holding DMAC Voting Common Shares, no par value per share 54,186 03 Jan 2022 By Children
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,750.
F2 Amount reflects the cancellation of 422 shares underlying deferred share units granted in lieu of Board committee retainers due to a change in Board committee memberships.
F3 Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 14,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.
F4 These voting common shares are held by 424822 Albert Ltd, of which Michael Giuffre has sole voting and dispositive power.